Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

被引：51
|
作者：
Kang, Jin [1 ,2 ,3 ]
Chen, Hua-Jun [2 ,3 ]
Wang, Zheng [4 ]
Liu, Jing [5 ]
Li, Bing [5 ]
Zhang, Tengfei [5 ]
Yang, Zhenfan [4 ]
Wu, Yi-Long [2 ,3 ,6 ]
Yang, Jin-Ji [1 ,2 ,3 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[4] AstraZeneca, Asia Innovat Med, Shanghai, Peoples R China
[5] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1016/j.jtho.2017.10.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E49 / E53
页数：5
相关论文
共 50 条
  • [21] Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance
    Wang, Jiao-Li
    Wang, Liu-sheng
    Zhu, Jun-qi
    Ren, Jie
    Wang, Di
    Luo, Man
    RESPIROLOGY CASE REPORTS, 2022, 10 (11):
  • [22] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro
    Franciele Hinterholz Knebel
    Fabiana Bettoni
    Rodrigo Saddi
    Karina Perez Sacardo
    Felipe Sales Nogueira Amorim Canedo
    João Victor Machado Alessi
    Andrea Kazumi Shimada
    José Flávio Gomes Marin
    Anamaria Aranha Camargo
    Artur Katz
    npj Precision Oncology, 5
  • [23] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Silva Almeida Ribeiro, Mauricio Fernando
    Knebel, Franciele Hinterholz
    Bettoni, Fabiana
    Saddi, Rodrigo
    Sacardo, Karina Perez
    Nogueira Amorim Canedo, Felipe Sales
    Machado Alessi, Joao Victor
    Shimada, Andrea Kazumi
    Gomes Marin, Jose Flavio
    Camargo, Anamaria Aranha
    Katz, Artur
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [24] Dramatic Response to. Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification
    Gainor, Justin F.
    Niederst, Matthew J.
    Lennerz, Jochen K.
    Dagogo-Jack, Ibiayi
    Stevens, Sara
    Shaw, Alice T.
    Sequist, Lecia V.
    Engelman, Jeffrey A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E83 - E85
  • [25] Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Lu, Yiyu
    Li, Zhihua
    Zhu, Huawei
    Zhao, Juan
    Xu, Mian
    Gu, Weiguang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (12) : 12886 - 12893
  • [26] Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Nakamura, Atsushi
    Sato, Yuki
    Azuma, Koichi
    Sakata, Shinya
    Tachihara, Motoko
    Ikeda, Satoshi
    Yokoyama, Toshihide
    Ito, Kentaro
    Yano, Yukihiro
    Matsumoto, Hirotaka
    Daga, Haruko
    Hata, Akito
    Sakai, Kazuko
    Chiba, Yasutaka
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2023, 24 (06) : 519 - +
  • [27] Analysis of primary and secondary EGFR-TKI resistance mutations evolution in 835 EGFR-mutant Chinese lung cancers.
    Dong, Xiaorong
    Zeng, Dongqiang
    Liu, Xinyi
    Huang, Mengli
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
    Wilgucki, Molly
    Yeung, Vincent
    Ho, Grace
    Montenegro, Gabriela L. Bravo
    Jones, Greg
    Reuss, Joshua E.
    V. Liu, Stephen
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (10):
  • [29] Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
    Deng, Lei
    Kiedrowski, Lesli A.
    Ravera, Elizabeth
    Cheng, Haiying
    Halmos, Balazs
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : E169 - E172
  • [30] Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C
    Li, Y. Q.
    Song, S. S.
    Jiang, S. H.
    Zhang, X. Y.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2622 - 2624
12345